

2015 PD THERAPEUTICS CONFERENCE

The Michael J. Fox Foundation for Parkinson's Research
9th Annual Parkinson's Disease Therapeutics Conference
November 3rd, 2015
New York, NY

Poster Session on Novel Therapeutic Targets and Tools

Nathalie Breyse, PhD, Lundbeck - "GPR6 antagonism as a Non-dopaminergic Therapy in Parkinson's Disease"

Anna Cartier, PhD, ICB International Inc – "Alpha-synuclein SMART Molecule: A Novel Blood-Brain Barrier Permeable Diagnostic Ligand for Parkinson's Disease"

Robert Friedland, MD, University of Louisville School of Medicine – "The Influence of Bacterial Amyloid on Alpha-synuclein Misfolding in the Rat"

Gregory Gerhardt, PhD, University of Kentucky Medical Center – "Therapeutic Development of siRNA Targeting Alpha-Synuclein"

Val Goodfellow, PhD, Califia Bio, Inc. – "CLFB-1134: MLK3 Inhibition in Pre-clinical Models of PD"

Sok Kean Khoo, PhD, Grand Valley State University – "Circulating microRNAs as Progression Biomarkers for Parkinson's Disease"

Laurie Mischley, ND, MPH, PhD(c), University of Washington – "Intranasal Glutathione in Parkinson's Disease"

Adrian Newman-Tancredi, PhD, DSc, Neurolix, Inc. – "NLX112, A Novel Candidate for the Treatment of L-DOPA-induced Dyskinesia: Behavioral and Neurochemical Profile in Rat"

Peggy Taylor, ScD, BioLegend, Inc. – "Toward Standardization of Alpha-synuclein Measurement: A Multi-pronged/Multi-center Approach for Assay Verification and Validation"

